Gustavo A. Rosario Benitez

Array ( [id] => 5584988 [patent_doc_number] => 20090104190 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-04-23 [patent_title] => 'HUMANIZED ANTI-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES' [patent_app_type] => utility [patent_app_number] => 12/246660 [patent_app_country] => US [patent_app_date] => 2008-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 4284 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0104/20090104190.pdf [firstpage_image] =>[orig_patent_app_number] => 12246660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12017104 [patent_doc_number] => 09809797 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-07 [patent_title] => 'Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression' [patent_app_type] => utility [patent_app_number] => 12/677035 [patent_app_country] => US [patent_app_date] => 2008-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10803 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12677035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12017104 [patent_doc_number] => 09809797 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-07 [patent_title] => 'Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression' [patent_app_type] => utility [patent_app_number] => 12/677035 [patent_app_country] => US [patent_app_date] => 2008-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10803 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12677035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5435514 [patent_doc_number] => 20090170101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-07-02 [patent_title] => 'IDENTIFICATION OF THYMICALLY DERIVED CD4 T CELLS BY PROTEIN TYROSINE KINASE 7 EXPRESSION' [patent_app_type] => utility [patent_app_number] => 12/238288 [patent_app_country] => US [patent_app_date] => 2008-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 12828 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0170/20090170101.pdf [firstpage_image] =>[orig_patent_app_number] => 12238288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5514253 [patent_doc_number] => 20090214559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-08-27 [patent_title] => 'Therapeutic Human Anti-IL-1R1 Monoclonal Antibody' [patent_app_type] => utility [patent_app_number] => 12/210313 [patent_app_country] => US [patent_app_date] => 2008-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 33541 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0214/20090214559.pdf [firstpage_image] =>[orig_patent_app_number] => 12210313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9008939 [patent_doc_number] => 08524233 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-09-03 [patent_title] => 'Monoclonal antibody and a method thereof' [patent_app_type] => utility [patent_app_number] => 12/921544 [patent_app_country] => US [patent_app_date] => 2008-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 33 [patent_no_of_words] => 15258 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12921544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4547711 [patent_doc_number] => 07820174 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-10-26 [patent_title] => 'T cell receptors and related materials and methods of use' [patent_app_type] => utility [patent_app_number] => 12/196833 [patent_app_country] => US [patent_app_date] => 2008-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 21035 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/820/07820174.pdf [firstpage_image] =>[orig_patent_app_number] => 12196833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7573093 [patent_doc_number] => 20110268749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-03 [patent_title] => 'TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-ALPHA2' [patent_app_type] => utility [patent_app_number] => 12/671652 [patent_app_country] => US [patent_app_date] => 2008-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 38612 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0268/20110268749.pdf [firstpage_image] =>[orig_patent_app_number] => 12671652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5520868 [patent_doc_number] => 20090028849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-29 [patent_title] => 'AGENTS AND METHODS FOR INHIBITION OF AIRWAY HYPERRESPONSIVENESS' [patent_app_type] => utility [patent_app_number] => 12/178923 [patent_app_country] => US [patent_app_date] => 2008-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12446 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0028/20090028849.pdf [firstpage_image] =>[orig_patent_app_number] => 12178923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8712839 [patent_doc_number] => 08398979 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-03-19 [patent_title] => 'Polypeptides, antibody variable domains and antagonists' [patent_app_type] => utility [patent_app_number] => 12/663502 [patent_app_country] => US [patent_app_date] => 2008-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 90 [patent_figures_cnt] => 80 [patent_no_of_words] => 55783 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12663502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5458875 [patent_doc_number] => 20090259027 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-10-15 [patent_title] => 'Human GM-CSF antibodies' [patent_app_type] => utility [patent_app_number] => 12/156063 [patent_app_country] => US [patent_app_date] => 2008-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8510 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0259/20090259027.pdf [firstpage_image] =>[orig_patent_app_number] => 12156063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4681719 [patent_doc_number] => 20080247945 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-10-09 [patent_title] => 'ANTI-IL-20 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION' [patent_app_type] => utility [patent_app_number] => 12/124946 [patent_app_country] => US [patent_app_date] => 2008-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70926 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0247/20080247945.pdf [firstpage_image] =>[orig_patent_app_number] => 12124946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5289929 [patent_doc_number] => 20090022659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-22 [patent_title] => 'Antibodies to TNF alpha and use thereof' [patent_app_type] => utility [patent_app_number] => 12/153611 [patent_app_country] => US [patent_app_date] => 2008-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 57367 [patent_no_of_claims] => 132 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0022/20090022659.pdf [firstpage_image] =>[orig_patent_app_number] => 12153611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6320682 [patent_doc_number] => 20100196402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-08-05 [patent_title] => 'Method for Predicting the Response of a Patient to Treatment with an Anti-TNF Alpha Antibody' [patent_app_type] => utility [patent_app_number] => 12/601173 [patent_app_country] => US [patent_app_date] => 2008-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 12761 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0196/20100196402.pdf [firstpage_image] =>[orig_patent_app_number] => 12601173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6234890 [patent_doc_number] => 20100266594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-10-21 [patent_title] => 'IL-9 IN FIBROTIC AND INFLAMMATORY DISEASE' [patent_app_type] => utility [patent_app_number] => 12/600583 [patent_app_country] => US [patent_app_date] => 2008-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 39044 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0266/20100266594.pdf [firstpage_image] =>[orig_patent_app_number] => 12600583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4675659 [patent_doc_number] => 20080213288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-09-04 [patent_title] => 'Combined Use Of A Modulator Of CD3 And A GLP-1 Compound' [patent_app_type] => utility [patent_app_number] => 12/114395 [patent_app_country] => US [patent_app_date] => 2008-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5912 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0213/20080213288.pdf [firstpage_image] =>[orig_patent_app_number] => 12114395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6574592 [patent_doc_number] => 20100129361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-05-27 [patent_title] => 'IMMUNOSUPPRESSION WITH ANTIBODY AGAINST ITM2A' [patent_app_type] => utility [patent_app_number] => 12/598567 [patent_app_country] => US [patent_app_date] => 2008-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 20474 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0129/20100129361.pdf [firstpage_image] =>[orig_patent_app_number] => 12598567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12741 [patent_doc_number] => 07807168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-10-05 [patent_title] => 'Selection of human TNFα specific antibodies' [patent_app_type] => utility [patent_app_number] => 12/100008 [patent_app_country] => US [patent_app_date] => 2008-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 47509 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/807/07807168.pdf [firstpage_image] =>[orig_patent_app_number] => 12100008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6228877 [patent_doc_number] => 20100183615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-22 [patent_title] => 'CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS' [patent_app_type] => utility [patent_app_number] => 12/594729 [patent_app_country] => US [patent_app_date] => 2008-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 51377 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0183/20100183615.pdf [firstpage_image] =>[orig_patent_app_number] => 12594729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4681799 [patent_doc_number] => 20080248025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-10-09 [patent_title] => 'Gamma Delta T Cells and Methods of Treatment of Interleukin-17 Related Conditions' [patent_app_type] => utility [patent_app_number] => 12/053310 [patent_app_country] => US [patent_app_date] => 2008-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 14698 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0248/20080248025.pdf [firstpage_image] =>[orig_patent_app_number] => 12053310 [rel_patent_id] =>[rel_patent_doc_number] =>)